Company / Capital Expenditures
KalVista Pharmaceuticals, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$434.0K
FY2025
5-year range
$42.0K / $1.2M
FY2021-FY2025
Trend
+0.0%
vs FY2024
Sector context
#142 of 194
Health Care
What the data says
At $434,000, KalVista Pharmaceuticals, Inc.'s capital expenditures ranks #142 of 194 in the Health Care sector. Capital Expenditures has fluctuated over the past 10 years, ranging from $11,000 in FY2018 to $1M in FY2017.
Based on SEC 10-K filings.
$434,000 in FY2025 with a 5-year CAGR of +39.6%.
Improved from $42,000 to $434,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -28.7%
- 5-Year CAGR
- +39.6%
- 10-Year CAGR
- -
Sector benchmark
#142 of 194 in Health CareTop 73% of 194This company $434.0K Sector average $117.5M
▼
-99.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +39.6%, indicating consistent growth.
- In FY2025, capital expenditures increased 0.0% year-over-year.
- Ranks #142 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2017.
Company context
Key Data Points
- Altman Z-Score -3.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $434.0K | +0.0% |
| FY2024 | $434.0K | +933.3% |
| FY2023 | $42.0K | -96.5% |
| FY2022 | $1.2M | +28.5% |
| FY2021 | $931.0K | +1035.4% |
| FY2020 | $82.0K | +10.8% |
| FY2019 | $74.0K | +572.7% |
| FY2018 | $11.0K | -99.2% |
| FY2017 | $1.4M | +1828.4% |
| FY2016 | $74.0K | -40.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026